Krivoborodov G G, Tur E I, Efremov N S, Shkolnikov M E
Department of Faculty Surgery, Urology of the Medical Faculty RNSMU n.a. N.I. Pirogov, RCRC of Gerontology.
Urologiia. 2016 Aug(4):29-34.
Evaluation of the efficacy and safety of different doses of trospium chloride in patients with idiopathic overactive bladder.
Large-scale observational program "Resource" included 669 patients with idiopathic OAB - 359 women and 310 men. At the first visit, all patients were assigned to use of trospium chloride at a standard dose of 45 mg per day. The results of treatment were evaluated during follow-up visits at 3, 6, 9 and 12 weeks. Depending on the results of examination, the dose was reduced in the presence of adverse events and increased in case of insufficient treatment effects.
After 12 weeks, 102 patients have been receiving the drug at a dose of 30 mg/day, 241 - at a dose of 45 mg/day, 257 - at a dose of 60 mg/day, and 22 - at a dose of 75 mg/day.
Individual approach to the selection of doses of trospium chloride in patients with idiopathic OAB can be quite effective and safe measure to achieve optimal clinical outcome with a good safety profile.
评估不同剂量的曲司氯铵治疗特发性膀胱过度活动症患者的疗效和安全性。
大规模观察项目“资源”纳入了669例特发性膀胱过度活动症患者，其中女性359例，男性310例。首次就诊时，所有患者均被指定使用标准剂量为每日45毫克的曲司氯铵。在第3、6、9和12周的随访中评估治疗结果。根据检查结果，出现不良事件时减少剂量，治疗效果不佳时增加剂量。
12周后，102例患者接受30毫克/天的药物治疗，241例接受45毫克/天的药物治疗，257例接受60毫克/天的药物治疗，22例接受75毫克/天的药物治疗。
对特发性膀胱过度活动症患者采用个体化方法选择曲司氯铵剂量，可能是实现最佳临床疗效且安全性良好的一种非常有效和安全的措施。
Zotero 插件